# Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
Canonical URL: https://biopharmsignal.com/news/NKTR/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026
Ticker: NKTR
Company: Nektar Therapeutics
Source: Nektar Therapeutics
Published: 2026-04-19 16:00 EST
Original Source URL: https://ir.nektar.com
## Summary

SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension

## Article Body
SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension
## Recent Company News
- 2026-05-27 22:15 EST — [Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: Nektar Therapeutics
- 2026-05-07 20:15 EST — [Nektar Therapeutics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2026-financial-results) — Source: Nektar Therapeutics
- 2026-05-01 20:39 EST — [Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Nektar Therapeutics
- 2026-04-28 22:00 EST — [Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets](https://biopharmsignal.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-7-2026-after-close-of-u-s-based-financial-markets) — Source: Nektar Therapeutics
- 2026-04-23 20:15 EST — [Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-closing-of-373-8-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares) — Source: Nektar Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)